Clinical Trials Browser

Prostatic Neoplasms × liposomal doxorubicin × Clear all

Prostatic Neoplasms

NCT00307294 2017-11-24

Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)

Phase 2 Completed

40 enrolled 8 charts

Genitourinary

Prostatic Neoplasms

NCT02262455 2017-02-13

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Phase 1 Completed

32 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Fallopian Tube Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT00176293 2015-04-21

Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer

Phase 2 Terminated

2 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00132756 2006-11-08

Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer

Phase 1/2 Terminated

30 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer

Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer

Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer